mylan
Photo courtesy of Mylan
29 November 2016Africa

Mylan enters MPP agreement over affordable hepatitis C generics

Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool (MPP), a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries.

Under the agreement, announced yesterday, November 28, Mylan will produce and market a generic version of Bristol-Myers Squibb’s Daklinza (daclatasvir).

The generic drug will be distributed in 112 low and middle income countries.

Rajiv Malik, president of Mylan, said: “We’re committed at Mylan to reducing the burden of hepatitis C on communities around the world by providing access to high quality medicines that treat the disease.

He added: “We are pleased to work together with the MPP and Bristol-Myers Squibb to help make daclatasvir available to low and middle income countries at affordable prices.”

According to the statement, 130 to 150 million people have chronic hepatitis C infection and the majority live in low and middle income countries.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
9 October 2017   Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.

More on this story

Biotechnology
9 October 2017   Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.

More on this story

Biotechnology
9 October 2017   Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.